152 related articles for article (PubMed ID: 20120033)
21. Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib.
Twardowski PW; Smith-Powell L; Carroll M; VanBalgooy J; Ruel C; Frankel P; Synold TW
Cancer Invest; 2008 Feb; 26(1):53-9. PubMed ID: 18181046
[TBL] [Abstract][Full Text] [Related]
22. A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment.
Solti M; Berd D; Mastrangelo MJ; Sato T
Melanoma Res; 2007 Aug; 17(4):225-31. PubMed ID: 17625452
[TBL] [Abstract][Full Text] [Related]
23. Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
Ott PA; Chang J; Madden K; Kannan R; Muren C; Escano C; Cheng X; Shao Y; Mendoza S; Gandhi A; Liebes L; Pavlick AC
Cancer Chemother Pharmacol; 2013 Jan; 71(1):183-91. PubMed ID: 23064957
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma.
Pflugfelder A; Eigentler TK; Keim U; Weide B; Leiter U; Ikenberg K; Berneburg M; Garbe C
PLoS One; 2011 Feb; 6(2):e16882. PubMed ID: 21359173
[TBL] [Abstract][Full Text] [Related]
25. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.
O'Day S; Gonzalez R; Lawson D; Weber R; Hutchins L; Anderson C; Haddad J; Kong S; Williams A; Jacobson E
J Clin Oncol; 2009 Nov; 27(32):5452-8. PubMed ID: 19826135
[TBL] [Abstract][Full Text] [Related]
26. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY
Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma.
Spitler LE; Boasberg P; O'Day S; Hamid O; Cruickshank S; Mesko S; Weber RW
Am J Clin Oncol; 2015 Feb; 38(1):61-7. PubMed ID: 25616203
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
[TBL] [Abstract][Full Text] [Related]
29. A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
Hamid O; Ilaria R; Garbe C; Wolter P; Maio M; Hutson TE; Arance A; Lorigan P; Lee J; Hauschild A; Mohr P; Hahka-Kemppinen M; Kaiser C; Turner PK; Conti I; Grob JJ
Cancer; 2014 Jul; 120(13):2016-24. PubMed ID: 24676877
[TBL] [Abstract][Full Text] [Related]
30. Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.
Narayanan S; Lam A; Vaishampayan U; Harshman L; Fan A; Pachynski R; Poushnejad S; Haas D; Li S; Srinivas S
Clin Genitourin Cancer; 2016 Oct; 14(5):432-437. PubMed ID: 27068017
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
[TBL] [Abstract][Full Text] [Related]
32. Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients.
Di Lorenzo G; Montesarchio V; Autorino R; Bellelli T; Longo N; Imbimbo C; Morelli E; Giannarini G; Mirone V; De Placido S
Cancer; 2009 Feb; 115(3):517-23. PubMed ID: 19117344
[TBL] [Abstract][Full Text] [Related]
33. Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma.
González-Cao M; Viteri S; Díaz-Lagares A; González A; Redondo P; Nieto Y; Espinós J; Chopitea A; Ponz M; Martín-Algarra S
Oncology; 2008; 74(1-2):12-6. PubMed ID: 18536525
[TBL] [Abstract][Full Text] [Related]
34. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
[TBL] [Abstract][Full Text] [Related]
35. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.
Homsi J; Bedikian AY; Kim KB; Papadopoulos NE; Hwu WJ; Mahoney SL; Hwu P
Melanoma Res; 2009 Aug; 19(4):238-42. PubMed ID: 19521262
[TBL] [Abstract][Full Text] [Related]
36. Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer.
Khan OA; Blann AD; Payne MJ; Middleton MR; Protheroe AS; Talbot DC; Taylor M; Kirichek O; Han C; Patil M; Harris AL
Br J Cancer; 2011 Jun; 104(12):1822-7. PubMed ID: 21587257
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Honecker F; Kollmannsberger C; Quietzsch D; Haag C; Schroeder M; Spott C; Hartmann JT; Baronius W; Hempel V; Kanz L; Bokemeyer C
Anticancer Drugs; 2002 Jun; 13(5):497-503. PubMed ID: 12045461
[TBL] [Abstract][Full Text] [Related]
38. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors.
Stempak D; Gammon J; Halton J; Moghrabi A; Koren G; Baruchel S
J Pediatr Hematol Oncol; 2006 Nov; 28(11):720-8. PubMed ID: 17114958
[TBL] [Abstract][Full Text] [Related]
39. Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium.
Hauke RJ; Infante JR; Rubin MS; Shih KC; Arrowsmith ER; Hainsworth JD
Melanoma Res; 2013 Dec; 23(6):468-73. PubMed ID: 23969699
[TBL] [Abstract][Full Text] [Related]
40. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J;
Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
